Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 9Neoplasm Metastasis 5Stomach Neoplasms 4Biliary Tract Neoplasms 4Neoplasms 3Esophageal Squamous Cell Carcinoma 3Small Cell Lung Carcinoma 2Sarcoma 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Locally Advanced Rectal Cancer 2Hodgkin Disease 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Recurrence 1Plaque, Atherosclerotic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Overall Survival 1Osteosarcoma 1NSCLC 1

Interventions

toripalimab 4pembrolizumab 4Gemcitabine 4tislelizumab 2durvalumab 2Nivolumab 2Cisplatin 2Carboplatin 2AZD4547 2tipifarnib 1tesetaxel 1sapanisertib 1regorafenib 1pyrotinib 1nintedanib 1famitinib 1disitamab vedotin 1camrelizumab 1bintrafusp alfa protein, human 1atezolizumab 1anlotinib 1aldesleukin 1advexin 1Vitamin B 12 1Trastuzumab 1Taxes 1Surgical Procedures, Operative 1Saline Solution 1Resistance Training 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Transitional Cell × Immune Checkpoint Inhibitors × Clear all
NCT05775874 2023-03-20

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Abbisko Therapeutics Co, Ltd

Phase 2 Unknown
80 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡